Robert Griffin

Federal Grant PI High Impact

Professor

University of Arkansas for Medical Sciences

faculty

Radiation Oncology, College of Medicine

71 h-index 499 pubs 25,813 cited

Research Areas

Cancer Treatment and Pharmacology Lung Cancer Diagnosis and Treatment Immune Response and Inflammation Pharmacological Effects and Toxicity Studies Cancer-related molecular mechanisms research Microbial infections and disease research Protein Structure and Dynamics Advanced Radiotherapy Techniques

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Robert Griffin is a Professor in the Department of Radiation Oncology at the University of Arkansas for Medical Sciences. His research interests include the development of novel therapeutic agents and understanding their mechanisms of action. Griffin has published work on targeted therapies for non-small cell lung cancer, specifically focusing on inhibitors of EGFR exon 20 insertion mutants, as exemplified by his publication on mobocertinib. He also investigates the design of novel macrocycles with potential therapeutic applications, including membrane-traversing properties.

Further research areas for Griffin include the identification of STING agonists for antitumor immunotherapy and the design of proteasome inhibitors with efficacy against malaria. His work also extends to the clinical pharmacology of next-generation kinase inhibitors, such as brigatinib. Griffin has a substantial publication record, with 285 total publications and an h-index of 34, indicating a significant research output and impact. He collaborates with researchers from institutions including the University of Arkansas at Little Rock and maintains an active research group and website.

Metrics

h-index: 71
Publications: 499
Citations: 25,813

Selected Publications

Pancreatic cancer extracellular vesicles stimulate Schwann cell activation and perineural invasion in vitro via IL-8/CCL2 (2025) DOI
Abstract B026: Pancreatic tumor extracellular vesicles induce perineural invasion in vitro via IL- 8/CCL2 (2024) DOI
The Radiosurgery Society Working Groups on GRID, LATTICE, Microbeam, and FLASH Radiotherapies: Advancements Symposium and Subsequent Progress Made (2024) DOI
Interrogating the Role of Endocytosis Pathway and Organelle Trafficking for Doxorubicin-Based Combination Ionic Nanomedicines (2024) DOI
Innovations in Physics, Biology and Clinical Translation of Spatially Fractionated and FLASH Radiotherapy (2024) DOI
Bystander Effects in Spatially Fractionated Radiation Therapy: From Molecule To Organism To Clinical Implications (2024) DOI
Doxorubicin-Based Ionic Nanomedicines for Combined Chemo-Phototherapy of Cancer (2024) DOI
Overview and Recommendations for Prospective Multi-institutional Spatially Fractionated Radiation Therapy Clinical Trials (2023) DOI
Cationic Porphyrin-Based Ionic Nanomedicines for Improved Photodynamic Therapy (2023) DOI
Morphological Effects and In Vitro Biological Mechanisms of Radiation-Induced Cell Killing by Gold Nanomaterials (2023) DOI
Exosomal MicroRNA and Protein Profiles of Hepatitis B Virus-Related Hepatocellular Carcinoma Cells (2023) DOI
Practice Patterns of Spatially Fractionated Radiation Therapy: A Clinical Practice Survey (2023) DOI
Pancreatic Tumor-Derived Extracellular Vesicles Stimulate Schwann Cell Phenotype Indicative of Perineural Invasion via IL-8 Signaling (2023) DOI
Preferential Tumor Vascular Damage Is the Common Antitumor Mechanism of High-Dose Hypofractionated Radiation Therapy: SABR, Spatially Fractionated Radiation Therapy, and FLASH Radiation Therapy (2023) DOI
Proteomic analysis of transcription factors involved in the alteration of ischemic mouse heart as modulated by MSC exosomes (2023) DOI

Grants & Funding

Detection of hypoxia markers in tumor exosomes using Raman spectroscopy University of Arkansas at Fayetteville Principal Investigator
Functional optical biomarkers of response to therapy in head and neck squamous cell carcinoma- Resubmission Arkansas Economic Development Commission - Pass Through: National Science Foundation Principal Investigator
Improvement of cellular immunotherapy during dysbiosis NIH/Nat. Cancer Institute Principal Investigator
RII Track-1: Arkansas ASSET Initiative III - Continuation Y5 - Continuation National Science Foundation - Pass Through: Arkansas Economic Development Commission Principal Investigator
Physiological Factors in Hyperthermia NIH Principal Investigator
Determination of functional and molecular biomarkers of treatment resistance with multimodal optical spectroscopy- Resubmission NIH/Nat. Cancer Institute - Pass Through: University of Arkansas at Fayetteville Co-Investigator
Functional optical biomarkers of response to therapy in head and neck squamous cell carcinoma- Resubmission Arkansas Economic Development Commission - Pass Through: National Science Foundation Principal Investigator
Functional optical biomarkers of response to therapy in head and neck squamous cell carcinoma- Resubmission Arkansas Economic Development Commission - Pass Through: National Science Foundation Principal Investigator